Stock Evaluator: Elanco Animal Health Incorporated (ELAN)

Elanco Animal Health Incorporated ELAN

$26.08 -0.39 -1.46%
July 31, 2026 12:01:13 PM EST November 10, 2021 Volume: 1,697,458
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Commentary & Analysis


Financial Summary

Share Statistics ELAN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $13,215.4 $569.9 81%
Shares Out (Mil) 506.0 44.8 89%
Institutional Ownership 99.3% 84.6% 87%
Float (Mil) 494.8 45.1 85%
Beta 1.70 0.67 87%
Avg Daily Volume (000s) 4,971 294 92%
Price Change
(52-week)
83.9% 65.2% 89%
Growth ELAN Industry
Median
Percentile
(All Stocks)
Sales (5yr) 7.6% 6.7% 48%
Net Income (5yr) 16.6% (2.0%) 67%
EPS (5yr) 18.4% 14.9% 65
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (14.9%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 12 14 14
Current EPS $0.269 $1.066 $1.196
Month Ago EPS $0.267 $1.066 $1.189
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS $0.289 $1.034 $1.167
Year/Year Chg 144.5% (326.8%) (390.6%)
Financials ELAN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4,893 $230 75%
Net Income (TTM) (Mil) ($242) ($11) 6%
EPS (TTM) ($0.487) ($0.600) 28%
Operating Cash Flow (TTM) (Mil) $577 ($6) 74%
Net Cash Flow (TTM) (Mil) ($59) $4 18%
Long-Term Debt (Q1) (Mil) $4,227 $7 84%
Enterprise Value (Q1) (Mil) $15,554 $493 80%
Valuation ELAN Industry
Median
Percentile
(All Stocks)
P/B 2.03 2.89 51%
P/E na 20.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios ELAN Industry
Median
Percentile
(All Stocks)
Gross Margin 55.1% 65.9% 67%
Net Margin (4.9%) (0.2%) 25%
ROA (1.8%) (25.5%) 35%
ROE (3.8%) (21.4%) 32%
Liabilities to Assets 50.8% 35.5% 43%
F-Score 4 3 34%

Elanco Animal Health Incorporated did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors